1-3 of 3
Elena Henkel
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial

Free
Sabine Kahl, Sofiya Gancheva, Klaus Straßburger, Christian Herder, Jürgen Machann, Hisayuki Katsuyama, Stefan Kabisch, Elena Henkel, Stefan Kopf, Merit Lagerpusch, Konstantinos Kantartzis, Yuliya Kupriyanova, Daniel Markgraf, Theresa van Gemert, Birgit Knebel, Martin F. Wolkersdorfer, Oliver Kuss, Jong-Hee Hwang, Stefan R. Bornstein, Christian Kasperk, Norbert Stefan, Andreas Pfeiffer, Andreas L. Birkenfeld, Michael Roden
Journal: Diabetes Care
Diabetes Care 2020;43(2):298–305
https://doi.org/10.2337/dc19-0641
Published: 20 September 2019
View articletitled, Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open the PDF for Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial in another window
Includes: Supplementary data
Journal Articles

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial

Free
Andrew J. Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G. Holst, Miriam P. Annett, Vanita R. Aroda
Journal: Diabetes Care
Diabetes Care 2018;41(2):258–266
https://doi.org/10.2337/dc17-0417
Published: 15 December 2017
View articletitled, Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial
Open the PDF for Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study

Free
Markolf Hanefeld, MD, PHD, Carsta Koehler, PHD, Katja Fuecker, DIPL CHEM, Elena Henkel, MD, Frank Schaper, MD, Theodora Temelkova-Kurktschiev, MD, PHD
Journal: Diabetes Care
Diabetes Care 2003;26(3):868–874
https://doi.org/10.2337/diacare.26.3.868
Published: 01 March 2003
View articletitled, Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study
Open the PDF for Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study in another window